Literature DB >> 16158186

Regulation of the extracellular signal-regulated kinases following acute and chronic opioid treatment.

W Bilecki1, G Zapart, A Ligeza, A Wawrzczak-Bargiela, M J Urbański, R Przewłocki.   

Abstract

The adaptations in extracellular signal-regulated kinase (ERK) pathway activity result in alterations in transcription of several genes that can be essential for development of both opioid tolerance and dependence. In this study, we investigated the effect of acute and prolonged opioid treatment on ERK pathway activity in SH-SY5Y cells. Acute administration of morphine and DAMGO stimulated ERK activity and this stimulation required activation of Ca(2+)/calmodulindependent kinase II (CaMKII) and protein kinase C (PKC). In contrast, prolonged morphine treatment decreased the level of phosphorylated ERK. The pr ecipitation of withdrawal further decreased the ERK1/2 activity. The principal finding of these studies is demonstration that the activation of CaMKII and PKC is required for ERK stimulation following acute opioid treatment while in a chronic morphine treatment and withdrawal, the up-regulation of PKC and CaMKII pathways seems to be engaged in the ERK inhibition. These results provide evidence that both opioid administration and opioid withdrawal, affecting similar intracellular pathways, can exert different effects on ERK activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16158186     DOI: 10.1007/s00018-005-5277-y

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  17 in total

Review 1.  Opioid receptor trafficking and signaling: what happens after opioid receptor activation?

Authors:  Jia-Ming Bian; Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2011-09-25       Impact factor: 5.046

2.  Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers.

Authors:  Raphael Rozenfeld; Lakshmi A Devi
Journal:  FASEB J       Date:  2007-03-23       Impact factor: 5.191

Review 3.  The role of mitogen-activated protein kinase (MAPK) in morphine tolerance and dependence.

Authors:  Yong Chen; Claudia Sommer
Journal:  Mol Neurobiol       Date:  2009-05-26       Impact factor: 5.590

Review 4.  The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence.

Authors:  Yanju Bao; Yebo Gao; Liping Yang; Xiangying Kong; Jing Yu; Wei Hou; Baojin Hua
Journal:  Channels (Austin)       Date:  2015-07-15       Impact factor: 2.581

5.  Opiate Exposure State Controls a D2-CaMKIIα-Dependent Memory Switch in the Amygdala-Prefrontal Cortical Circuit.

Authors:  Laura G Rosen; Jordan Zunder; Justine Renard; Jennifer Fu; Walter Rushlow; Steven R Laviolette
Journal:  Neuropsychopharmacology       Date:  2015-07-15       Impact factor: 7.853

6.  Morphine induces redox-based changes in global DNA methylation and retrotransposon transcription by inhibition of excitatory amino acid transporter type 3-mediated cysteine uptake.

Authors:  Malav Trivedi; Jayni Shah; Nathaniel Hodgson; Hyang-Min Byun; Richard Deth
Journal:  Mol Pharmacol       Date:  2014-02-25       Impact factor: 4.436

Review 7.  Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment.

Authors:  Sandra D Comer; Catherine M Cahill
Journal:  Neurosci Biobehav Rev       Date:  2018-12-05       Impact factor: 8.989

8.  Ligand-biased activation of extracellular signal-regulated kinase 1/2 leads to differences in opioid induced antinociception and tolerance.

Authors:  Erin N Bobeck; Susan L Ingram; Sam M Hermes; Sue A Aicher; Michael M Morgan
Journal:  Behav Brain Res       Date:  2015-10-20       Impact factor: 3.332

Review 9.  Phosphoinositide pathway and the signal transduction network in neural development.

Authors:  Vincenza Rita Lo Vasco
Journal:  Neurosci Bull       Date:  2012-11-14       Impact factor: 5.203

10.  Neurotrophic actions of PACAP-38 and LIF on human neuroblastoma SH-SY5Y cells.

Authors:  T K Monaghan; C Pou; C J MacKenzie; R Plevin; E M Lutz
Journal:  J Mol Neurosci       Date:  2008-05-28       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.